Cosentyx, a medication used to treat chronic plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, is a biologic medication that is administered via injection [1]. As with any medication, patients who receive Cosentyx may experience side effects.

According to the U.S. Food and Drug Administration (FDA), common side effects of Cosentyx include injection-site reactions such as redness, itching, swelling, or warmth [2]. Other side effects include headache, fatigue, diarrhea, and nasopharyngitis (inflammation of the nasal passages) [3].

In addition to these common side effects, Cosentyx has been linked to several more serious potential side effects. These include an increased risk of infections, such as upper respiratory tract infections, bronchitis, and sinusitis [4]. Patients should seek medical attention if they experience any unusual symptoms, such as difficulty breathing, coughing, or fever.

Additionally, Cosentyx has been associated with various immune-related side effects, including autoimmune hepatitis, hypersensitivity reactions, and inflammatory bowel disease (including Crohn's disease and ulcerative colitis) [5]. Patients taking Cosentyx should be closely monitored by a healthcare provider for these potential side effects.

To mitigate the risk of side effects, patients should inform their healthcare provider about any pre-existing medical conditions, as well as any medications they are currently taking. Regular monitoring, including biweekly injections, is a common practice for patients taking Cosentyx [1].

It is essential for patients to work closely with their healthcare provider to minimize the risk of side effects and ensure the medication is working effectively. According to a resource from the CenterWatch Clinical Trials database, Cosentyx's manufacturer, Novartis, conducts ongoing research to further evaluate the medication's safety and efficacy [6].

Please refer to DrugPatentWatch.com for detailed information on Cosentyx patents and pharmaceutical industry updates [7].

Sources:

[1] https://www.cosentyxhcp.com/

[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2016/125553s014lbl.pdf

[3] https://www.cosentyxhcp.com/pdf/PI/ CosentyxPI.pdf

[4] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-expands-warning-cardiovascular-risk-and-inflammatory-disease

[5] https://www.cosentyxhcp.com/safety/

[6] https://www.centerwatch.com/drug-information/drug-profiles/1843/cosentyx

[7] https://www.drugpatentwatch.com/drugs/cosentyx